aibio
Company Updates ·
Neuphoria extends its rights agreement to October 27, 2027
The board approved Amendment No. 1 to the rights agreement with Computershare, moving the final expiration date to the close of business on October 27, 2027.
NEUP Neuphoria Therapeutics Inc.
Neuphoria Therapeutics (NEUP) news NEUP going concern, offering and Nasdaq notice news
Latest Neuphoria Therapeutics news
- Mergers
Neuphoria and Scancell agree to all-share merger with up to $89 million financing
Scancell will acquire Neuphoria in an all-share deal that would create a combined company listed on Nasdaq, alongside a financing of up to $89 million.
- Listings
Neuphoria Therapeutics gets Nasdaq extension to December 29, 2025 to hold annual meeting
Nasdaq accepted Neuphoria's plan on September 10, 2025, after a July 18, 2025 notice that it had not held an annual meeting. The company has until December 29, 2025 and says it will file its Form 10-K on or before September 29, 2025.
- Listings
Neuphoria Therapeutics gets Nasdaq notice over annual meeting requirement
Neuphoria Therapeutics received a Nasdaq notice that it did not hold an annual meeting within a year of its June 30, 2024 fiscal year end. It has until September 1, 2025 to submit a plan, and its annual report for that year carries a going-concern warning with cash that, combined with an ATM facility, is expected to fund work into late in the first quarter of fiscal 2026.
- Distress
Neuphoria Therapeutics delays quarterly report for period ended March 31, 2025
Neuphoria said it needs more time to compile supporting documents and let its auditor finish its review. It expects to file within the five-day extension period.
- Mergers
Bionomics (now Neuphoria Therapeutics) wins court approval for its US move
The Supreme Court of New South Wales approved the scheme of arrangement. Neuphoria shares are expected to start trading on Nasdaq as NEUP on December 24, 2024.
What Neuphoria Therapeutics does
Neuphoria Therapeutics Inc. is a Delaware clinical-stage biotechnology company. Its lead product candidate, BNC210, is an oral, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. BNC210 did not meet the primary endpoint of its Phase 3 AFFIRM-1 trial in social anxiety disorder, announced October 20, 2025, and the company discontinued that program. Its PTSD program, which met the primary endpoint of the Phase 2b ATTUNE trial, is clinic-ready with no active clinical trial. After restructuring, Neuphoria retained only one full-time employee, and its partners continue programs independently. These include Merck's alpha7 positive allosteric modulator program, the KAT6 program that Pfizer controls and that has entered Phase 3, and Carina's CNA3103 CAR-T candidate in a Phase 1/2a trial in metastatic colorectal cancer. On July 23, 2026, Neuphoria entered an Agreement and Plan of Merger with Scancell Holdings plc. If completed, each share would convert into the right to receive Scancell American Depositary Shares and one contingent value right. The parties expect the transactions to close in late calendar 2026, but there is no assurance they will close.
| Product or program | What it is | Stage |
|---|---|---|
| BNC210 | Oral alpha7 nicotinic acetylcholine receptor negative allosteric modulator | Clinic-ready for PTSD; no active clinical trial |
| Merck alpha7 PAM program (MK-4334) | Alpha7 receptor positive allosteric modulators partnered with Merck | MK-4334 completed Phase 1 studies |
| KAT6 program (Pfizer) | Program licensed through CTx CRC to Pfizer | Entered Phase 3 |
| CNA3103 | LGR5-targeted CAR-T candidate in metastatic colorectal cancer, controlled by Carina | Phase 1/2a |
Neuphoria Therapeutics annual financials
| Line | FY ended Jun 30, 2026 | FY ended Jun 30, 2025 |
|---|---|---|
| Revenue | $1.2 million | $15.6 million |
| Research and development | $9.0 million | |
| Net income (loss) | -$13.5 million | -$369,632 |
| Cash from operations | -$12.4 million | $77,229 |
| Cash and equivalents | $19.9 million | $14.2 million |
Questions about Neuphoria Therapeutics
Has Neuphoria Therapeutics issued a going-concern warning?
Our latest story on this, dated Jul 18, 2025: "Neuphoria Therapeutics gets Nasdaq notice over annual meeting requirement". The story links the filing or release it is based on. Read the story.
Has Neuphoria Therapeutics raised money recently?
Our latest story on this, dated Jul 18, 2025: "Neuphoria Therapeutics gets Nasdaq notice over annual meeting requirement". The story links the filing or release it is based on. Read the story.
Has Neuphoria Therapeutics received a Nasdaq deficiency notice?
Our latest story on this, dated Jul 18, 2025: "Neuphoria Therapeutics gets Nasdaq notice over annual meeting requirement". The story links the filing or release it is based on. Read the story.
Is Neuphoria Therapeutics involved in a merger or acquisition?
Our latest story on this, dated Jul 23, 2026: "Neuphoria and Scancell agree to all-share merger with up to $89 million financing". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Neuphoria Therapeutics?
Neuphoria Therapeutics Inc. trades under the ticker NEUP on NASDAQ.
Where is Neuphoria Therapeutics listed?
Neuphoria Therapeutics Inc. is listed on NASDAQ.
What is the SEC CIK of Neuphoria Therapeutics?
The SEC Central Index Key (CIK) for Neuphoria Therapeutics Inc. is 1191070. Its filings are on SEC EDGAR.
How many shares does Neuphoria Therapeutics have outstanding?
5,411,334 shares as of 2026-09-17, per the cover page of its 10-K filed 2026-09-18.
Which country or territory is Neuphoria Therapeutics listed under?
Our directory records Neuphoria Therapeutics Inc. under United States.
What does Neuphoria Therapeutics do?
Our directory classifies Neuphoria Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Neuphoria Therapeutics?
The ISIN recorded for Neuphoria Therapeutics Inc. is US64136E1029.
Does aibio.space cover Neuphoria Therapeutics?
aibio.space lists Neuphoria Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Neuphoria Therapeutics incorporated?
SEC records list its state or country of incorporation as C3.
What does Neuphoria Therapeutics develop?
Neuphoria Therapeutics Inc. is a Delaware clinical-stage biotechnology company. Its lead product candidate, BNC210, is an oral, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor.
What is BNC210 from Neuphoria Therapeutics?
BNC210: Oral alpha7 nicotinic acetylcholine receptor negative allosteric modulator Stage: Clinic-ready for PTSD; no active clinical trial.
Investor discussion: Neuphoria Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,5.01,7.01,9.01). Source
- Distress
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
- Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,3.03,5.03,8.01,9.01). Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
- Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
- Distress
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
- Listings
Filed to end its SEC reporting. SEC Form 15-12G. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,3.01,3.02,3.03,5.01,5.02,5.03,5.05,8.01,9.01). Source
- Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01,9.01). Source
- Financings
Reported a financing. SEC Form S-3. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Stock chart
SEC filings and registration
- SEC name
- Neuphoria Therapeutics Inc.
- CIK
- 1191070
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- NEUP (Nasdaq)
- State or country of incorporation
- C3
- Fiscal year ends
- June 30
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Business address
- 100 SUMMIT DR, BURLINGTON, MA, 01803
- Phone
- 781-439-5551
- Shares outstanding
- 5,411,334 as of 2026-09-17 (10-K filed 2026-09-18)
- Former names
- BIONOMICS LIMITED/FI
Recent filings
Listing details
- Company
- Neuphoria Therapeutics Inc.
- Ticker
- NEUP
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US64136E1029
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction